Personalized MRD

Liquid biopsy assays for personalized minimal residual disease (MRD), a cutting-edge technology revolutionizing oncological treatment monitoring and relapse prediction in cancer patients. Unlike traditional MRD assays that primarily target somatic mutations, our approach focuses on epigenetic changes, which are more prevalent and widespread in cancer. By analyzing DNA methylation alterations and fragmentation patterns in circulating tumor DNA (ctDNA), our assays distinguish cancerous from noncancerous circulating cell-free DNA (ccfDNA).